Area of research
Cardiology and Cardiovascular Medicine · Surgery
Research interest
Research interests include Coronary Interventions and Diagnostics, Antiplatelet Therapy and Cardiovascular Diseases, Acute Myocardial Infarction Research, and Atrial Fibrillation Management and Outcomes.
P2Y<sub>12</sub>inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
In-hospital platelet count dynamics in patients with acute coronary syndrome
Dinámica del recuento plaquetario intrahospitalario en pacientes con síndrome coronario agudo
Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention
Risk Burden of Cancer in Patients Treated With Abbreviated Dual Antiplatelet Therapy After PCI: Analysis of Multicenter Controlled High-Bleeding Risk Trials
Bivalirudin vs Heparin Anticoagulation in STEMI
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis
Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials
Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials
1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI
Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI
Sex‐Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum
Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials
Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk
Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction